☒ Form 20-F | ☐ Form 40-F |
UNILEVER PLC | |||
Date: 28 July 2026 | By: | /s/ P. Kakkad | |
Name : | P. Kakkad | ||
Title: | Chief Legal Officer and Group Company Secretary | ||
First Half Key Highlights |
First Half Key Figures |
Underlying performance | GAAP measures | ||||||
(unaudited) | 2026 | vs 2025(b) | 2026 | vs 2025(b) | |||
First Half | |||||||
Underlying sales growth (USG) | 4.8% | Turnover | €25.6bn | 0.5% | |||
Beauty & Wellbeing | 5.9% | Beauty & Wellbeing | €6.5bn | 0.3% | |||
Personal Care | 4.8% | Personal Care | €6.8bn | 4.2% | |||
Home Care | 7.6% | Home Care | €6.0bn | 1.5% | |||
Foods | 1.2% | Foods | €6.3bn | (4.0)% | |||
Underlying operating profit | €5.2bn | 0.9% | Operating profit | €4.9bn | 2.6% | ||
Underlying operating margin | 20.3% | 10bps | Operating margin | 19.1% | 40bps | ||
Underlying earnings per share | €1.61 | 2.4% | Diluted earnings per share | €1.38 | (2.5)% | ||
Free cash flow | €1.5bn | €0.5bn | Net profit | €3.3bn | (3.5)% | ||
Second Quarter | |||||||
USG | 5.8% | Turnover | €13.0bn | 3.8% | |||
Quarterly dividend payable in September 2026 (a) | €0.4664 | per share(b) | |||||
Chief Executive Officer Statement |
Outlook |
First Half Review: Unilever Group |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change |
First Half | €25.6bn | 4.8% | 4.2% | 0.6% | 0.7% | (4.9)% | 0.5% |
Second Quarter | €13.0bn | 5.8% | 5.5% | 0.2% | 0.6% | (2.4)% | 3.8% |
First Half Review: Unilever Group (continued) |
(unaudited) | UOP | UOP growth | UOM% | Change in UOM | OP | OP growth | OM% | Change in OM |
First Half | €5.2bn | 0.9% | 20.3% | 10bps | €4.9bn | 2.6% | 19.1% | 40bps |
First Half Review: Unilever Group (continued) |
Conference Call |
Upcoming Events |
Date | Events |
4 September 2026 | Hindustan Unilever Investor Event 2026 (Mumbai, India) |
28 October 2026 | Q3 2026 Trading Statement |
4 November 2026 | Unilever Investor Event 2026 (New York, USA) |
First Half Review: Business Groups |
First Half 2026 | Second Quarter 2026 | |||||||||
(unaudited) | Turnover | USG | UVG | UPG | UOM | Change in UOM | Turnover | USG | UVG | UPG |
Unilever | €25.6bn | 4.8% | 4.2% | 0.6% | 20.3% | 10bps | €13.0bn | 5.8% | 5.5% | 0.2% |
Beauty & Wellbeing | €6.5bn | 5.9% | 4.5% | 1.3% | 19.5% | 10bps | €3.4bn | 8.1% | 6.9% | 1.1% |
Personal Care | €6.8bn | 4.8% | 4.1% | 0.7% | 22.2% | 10bps | €3.5bn | 5.9% | 6.8% | (0.9)% |
Home Care | €6.0bn | 7.6% | 7.4% | 0.2% | 15.8% | 30bps | €3.0bn | 9.1% | 8.6% | 0.5% |
Foods | €6.3bn | 1.2% | 1.2% | —% | 23.3% | 0bps | €3.1bn | 0.2% | (0.1)% | 0.2% |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €6.5bn | 5.9% | 4.5% | 1.3% | 0.8% | (6.0)% | 0.3% | 19.5% | 10bps |
Second Quarter | €3.4bn | 8.1% | 6.9% | 1.1% | 1.0% | (3.2)% | 5.7% |
First Half Review: Business Groups (continued) |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €6.8bn | 4.8% | 4.1% | 0.7% | 4.0% | (4.5)% | 4.2% | 22.2% | 10bps |
Second Quarter | €3.5bn | 5.9% | 6.8% | (0.9)% | 3.3% | (2.0)% | 7.3% |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €6.0bn | 7.6% | 7.4% | 0.2% | (0.5)% | (5.2)% | 1.5% | 15.8% | 30bps |
Second Quarter | €3.0bn | 9.1% | 8.6% | 0.5% | (0.7)% | (3.0)% | 5.0% |
First Half Review: Business Groups (continued) |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €6.3bn | 1.2% | 1.2% | —% | (1.5)% | (3.7)% | (4.0)% | 23.3% | 0bps |
Second Quarter | €3.1bn | 0.2% | (0.1)% | 0.2% | (1.4)% | (1.5)% | (2.7)% |
First Half Review: Geographical Areas |
First Half 2026 | Second Quarter 2026 | |||||||
(unaudited) | Turnover | USG | UVG | UPG | Turnover | USG | UVG | UPG |
Unilever | €25.6bn | 4.8% | 4.2% | 0.6% | €13.0bn | 5.8% | 5.5% | 0.2% |
Asia Pacific Africa | €11.3bn | 7.3% | 6.1% | 1.2% | €5.7bn | 8.8% | 7.2% | 1.5% |
The Americas | €9.7bn | 4.6% | 4.2% | 0.4% | €5.1bn | 5.7% | 6.2% | (0.5)% |
Europe | €4.6bn | (0.9)% | (0.2)% | (0.6)% | €2.2bn | (1.3)% | 0.3% | (1.6)% |
First Half 2026 | Second Quarter 2026 | |||||||
(unaudited) | Turnover | USG | UVG | UPG | Turnover | USG | UVG | UPG |
Emerging markets | €15.4bn | 7.0% | 5.8% | 1.2% | €7.8bn | 8.3% | 7.4% | 0.9% |
Developed markets | €10.2bn | 1.5% | 1.9% | (0.4)% | €5.2bn | 2.0% | 2.8% | (0.8)% |
North America | €5.7bn | 2.7% | 3.2% | (0.5)% | €3.0bn | 3.6% | 4.4% | (0.9)% |
Latin America | €4.0bn | 7.6% | 5.7% | 1.7% | €2.1bn | 8.9% | 8.8% | 0.1% |
First Half Review: Geographical Areas (continued) |
Additional commentary on the financial statements - First Half |
Additional commentary on the financial statements - First Half (continued) |
Non-GAAP measures |
Half year average rate in 2026 | Half year average rate in 2025 | |
Brazilian real (€1 = BRL) | 6.013 | 6.281 |
Chinese yuan (€1 = CNY) | 8.015 | 7.895 |
Indian rupee (€1 = INR) | 108.565 | 93.749 |
Indonesia rupiah (€1 = IDR) | 20,046 | 17,874 |
Mexican peso (€1 = MXN) | 20.414 | 21.788 |
Philippine peso (€1 = PHP) | 69.928 | 62.192 |
Turkish lira (€1 = TRY) | 52.003 | 40.649 |
UK pound sterling (€1 = GBP) | 0.868 | 0.842 |
US dollar (€1 = US$) | 1.167 | 1.088 |
Non-GAAP measures (continued) |
(unaudited) | Beauty & Wellbeing | Personal Care | Home Care | Foods | Total |
Second Quarter | |||||
Turnover (€ million) | |||||
2025 | 3,219 | 3,296 | 2,865 | 3,187 | 12,567 |
2026 | 3,403 | 3,535 | 3,009 | 3,099 | 13,046 |
Turnover growth (%) | 5.7 | 7.3 | 5.0 | (2.7) | 3.8 |
Effect of acquisitions (%) | 1.1 | 3.4 | – | – | 1.2 |
Effect of disposals (%) | (0.2) | – | (0.7) | (1.4) | (0.6) |
Effect of currency-related items (%), of which: | (3.2) | (2.0) | (3.0) | (1.5) | (2.4) |
Exchange rates changes (%) | (3.5) | (2.4) | (3.6) | (1.7) | (2.8) |
Extreme price growth in hyperinflationary markets* (%) | 0.3 | 0.4 | 0.6 | 0.2 | 0.4 |
Underlying sales growth (%) | 8.1 | 5.9 | 9.1 | 0.2 | 5.8 |
First Half | |||||
Turnover (€ million) | |||||
2025 | 6,489 | 6,545 | 5,904 | 6,568 | 25,506 |
2026 | 6,509 | 6,817 | 5,992 | 6,305 | 25,623 |
Turnover growth (%) | 0.3 | 4.2 | 1.5 | (4.0) | 0.5 |
Effect of acquisitions (%) | 0.9 | 4.0 | – | – | 1.3 |
Effect of disposals (%) | (0.2) | – | (0.5) | (1.5) | (0.5) |
Effect of currency-related items (%), of which: | (6.0) | (4.5) | (5.2) | (3.7) | (4.9) |
Exchange rates changes (%) | (6.2) | (4.9) | (5.7) | (3.9) | (5.1) |
Extreme price growth in hyperinflationary markets* (%) | 0.2 | 0.4 | 0.5 | 0.2 | 0.3 |
Underlying sales growth (%) | 5.9 | 4.8 | 7.6 | 1.2 | 4.8 |
(unaudited) | Asia Pacific Africa | The Americas | Europe | Total |
Second Quarter | ||||
Turnover (€ million) | ||||
2025 | 5,531 | 4,680 | 2,356 | 12,567 |
2026 | 5,694 | 5,067 | 2,285 | 13,046 |
Turnover growth (%) | 2.9 | 8.3 | (3.0) | 3.8 |
Effect of acquisitions (%) | 0.1 | 3.1 | – | 1.2 |
Effect of disposals (%) | (0.2) | (0.6) | (1.4) | (0.6) |
Effect of currency-related items (%), of which: | (5.2) | – | (0.4) | (2.4) |
Exchange rates changes (%) | (5.8) | (0.3) | (0.4) | (2.8) |
Extreme price growth in hyperinflationary markets* (%) | 0.6 | 0.3 | – | 0.4 |
Underlying sales growth (%) | 8.8 | 5.7 | (1.3) | 5.8 |
First Half | ||||
Turnover (€ million) | ||||
2025 | 11,400 | 9,424 | 4,682 | 25,506 |
2026 | 11,298 | 9,756 | 4,569 | 25,623 |
Turnover growth (%) | (0.9) | 3.5 | (2.4) | 0.5 |
Effect of acquisitions (%) | 0.2 | 3.0 | 0.5 | 1.3 |
Effect of disposals (%) | (0.2) | (0.4) | (1.6) | (0.5) |
Effect of currency-related items (%), of which: | (7.7) | (3.5) | (0.4) | (4.9) |
Exchange rates changes (%) | (8.2) | (3.7) | (0.4) | (5.1) |
Extreme price growth in hyperinflationary markets* (%) | 0.5 | 0.3 | – | 0.3 |
Underlying sales growth (%) | 7.3 | 4.6 | (0.9) | 4.8 |
Non-GAAP measures (continued) |
Non-GAAP measures (continued) |
€ million | First Half | |
(unaudited) | 2026 | 2025(f) |
Non-underlying items within operating profit before tax | (308) | (386) |
Acquisition and disposal-related costs(a) | (180) | (117) |
Gain on disposal of group companies(b) | 70 | 47 |
Restructuring costs(c) | (131) | (265) |
Impairments | (13) | (42) |
Other(d) | (54) | (9) |
Tax on non-underlying items within operating profit | 10 | 81 |
Non-underlying items within operating profit after tax | (298) | (305) |
Non-underlying items not in operating profit but within net profit before tax | (85) | (25) |
Net monetary loss arising from hyperinflationary economies | (85) | (25) |
Tax impact of non-underlying items not in operating profit but within net profit, including non-underlying tax items(e) | (99) | (5) |
Non-underlying items not in operating profit but within net profit after tax | (184) | (30) |
Non-underlying items after tax | (482) | (335) |
Attributable to: | ||
Non-controlling interests | 2 | (9) |
Shareholders’ equity | (484) | (326) |
€ million | First Half | |
(unaudited) | 2026 | 2025(a) |
Operating profit | 4,885 | 4,762 |
Non-underlying items within operating profit | 308 | 386 |
Underlying operating profit | 5,193 | 5,148 |
Turnover | 25,623 | 25,506 |
Operating margin (%) | 19.1 | 18.7 |
Underlying operating margin (%) | 20.3 | 20.2 |
Non-GAAP measures (continued) |
€ million | First Half | |
(unaudited) | 2026 | 2025(a) |
Taxation | 1,368 | 1,164 |
Tax impact of: | ||
Non-underlying items within operating profit | 10 | 81 |
Non-underlying items not in operating profit but within net profit | (99) | (5) |
Taxation before tax impact of non-underlying items | 1,279 | 1,240 |
Profit before taxation | 4,659 | 4,575 |
Share of net profit of joint ventures and associates | (140) | (146) |
Profit before tax excluding share of net profit of joint ventures and associates | 4,519 | 4,429 |
Non-underlying items within operating profit before tax | 308 | 386 |
Non-underlying items not in operating profit but within net profit before tax | 85 | 25 |
Profit before tax excluding non-underlying items before tax and share of net profit of joint ventures and associates | 4,912 | 4,840 |
Effective tax rate (%) | 30.3 | 26.3 |
Underlying effective tax rate (%) | 26.0 | 25.6 |
€ million | First Half | |
(unaudited) | 2026 | 2025(a) |
Net profit | 3,291 | 3,411 |
Non-controlling interest | (267) | (286) |
Net profit attributable to shareholders’ equity - used for basic and diluted earnings per share | 3,024 | 3,125 |
Post-tax impact of non-underlying items attributable to shareholders’ equity | 484 | 326 |
Underlying profit attributable to shareholders’ equity - used for basic and diluted earnings per share | 3,508 | 3,451 |
Diluted average number of shares (millions of share units) | 2,183 | 2,200 |
Diluted EPS (€) | 1.38 | 1.42 |
Underlying EPS – diluted (€) | 1.61 | 1.57 |
Non-GAAP measures (continued) |
€ million | As at 30 June 2026 | As at 31 December 2025 | As at 30 June 2025 |
(unaudited) | |||
Total financial liabilities | (32,110) | (28,278) | (32,025) |
Current financial liabilities | (8,142) | (2,582) | (7,155) |
Non-current financial liabilities | (23,968) | (25,696) | (24,870) |
Cash and cash equivalents as per balance sheet | 4,726 | 3,941 | 4,344 |
Cash and cash equivalents as per cash flow statement | 4,671 | 3,870 | 4,268 |
Add: bank overdrafts deducted therein | 55 | 65 | 70 |
Less: cash and cash equivalents held for sale | – | 6 | 6 |
Other current financial assets | 1,322 | 1,121 | 1,123 |
Non-current financial asset derivatives that relate to financial liabilities | 101 | 140 | 203 |
Net debt | (25,961) | (23,076) | (26,355) |
€ million | First Half | |
(unaudited) | 2026 | 2025(a) |
Net profit from continuing operations | 3,291 | 3,411 |
Net finance costs | 302 | 277 |
Net monetary loss arising from hyperinflationary economies | 85 | 25 |
Share of net profit of joint ventures and associates | (140) | (146) |
Other loss/(income) from non-current investments and associates | (21) | 31 |
Taxation | 1,368 | 1,164 |
Operating profit | 4,885 | 4,762 |
Depreciation and amortisation | 619 | 604 |
Earnings before interest, taxes, depreciation and amortisation (EBITDA) | 5,504 | 5,366 |
Non-underlying items within operating profit | 308 | 386 |
Underlying earnings before interest, taxes, depreciation and amortisation (UEBITDA) | 5,812 | 5,752 |
Non-GAAP measures (continued) |
€ million | First Half | |
(unaudited) | 2026 | 2025(a) |
Cash flow from operating activities | 4,347 | 3,147 |
Income tax paid | (1,770) | (1,128) |
Net capital expenditure | (599) | (480) |
Net interest paid | (429) | (455) |
Free cash flow | 1,549 | 1,084 |
Net cash flow used in investing activities | (1,040) | (527) |
Net cash flow used in financing activities | (1,186) | (3,045) |
Other Information |
Principal Risk Factors |
Cautionary Statement |
Directors' Responsibility Statement |
Enquiries |
Media: Media Relations Team | Investors: Investor Relations Team | ||
UK | +44 77 4249 0136 | ||
or | +44 77 7999 9683 | ||
NL | +31 63 029 6394 | ||
or | +31 61 500 8293 | ||
Consolidated income statement |
€ million | First Half | ||
(unaudited) | 2026 | 2025(a) | Change |
Turnover | 0.5% | ||
Operating profit | 2.6% | ||
Net finance costs | ( | ( | |
Pensions and similar obligations | |||
Finance income | |||
Finance costs | ( | ( | |
Net monetary loss arising from hyperinflationary economies | ( | ( | |
Share of net profit of joint ventures and associates | |||
Other income (loss) from non-current investments and associates | ( | ||
Profit before taxation | 1.8% | ||
Taxation | ( | ( | |
Net profit from continuing operations | (3.5)% | ||
Profit after taxation from discontinued operations | ( | ||
Gain on disposal of discontinued operations | |||
Net profit from discontinued operations | |||
Total net profit | |||
Attributable to: | |||
Non-controlling interests | |||
Shareholders’ equity | (5.6)% | ||
Total profit attributable to shareholders’ equity arises from: | |||
Continuing operations | |||
Discontinued operations | |||
Total profit attributable to non-controlling interests arises from: | |||
Continuing operations | |||
Discontinued operations | ( | ||
Earnings per share | |||
Basic earnings per share (euros) | (5.0)% | ||
Basic earnings per share (€) from continuing operations | (2.6)% | ||
Basic earnings per share (€) from discontinued operations | (24.1)% | ||
Diluted earnings per share (euros) | (4.9)% | ||
Diluted earnings per share (€) from continuing operations | (2.5)% | ||
Diluted earnings per share (€) from discontinued operations | (24.0)% |
Consolidated statement of comprehensive income |
€ million | First Half | |
(unaudited) | 2026 | 2025(a) |
Net profit | ||
Other comprehensive income from continuing operations | ||
Items that will not be reclassified to profit or loss, net of tax: | ||
Gains/(losses) on equity instruments measured at fair value through other comprehensive income | ( | |
Remeasurement of defined benefit pension plans | ( | |
Items that may be reclassified subsequently to profit or loss, net of tax: | ||
Gains/(losses) on cash flow hedges | ( | |
Currency retranslation gains/(losses) | ( | |
Total comprehensive income from continuing operations | ( | |
Other comprehensive income from discontinued operations | ( | |
Total comprehensive income | ||
Attributable to: | ||
Non-controlling interests | ||
Shareholders’ equity | ||
Consolidated statement of changes in equity |
(unaudited) | ||||||||
€ million | Called up share capital | Share premium account | Unification reserve | Other reserves | Retained profit | Total | Non- controlling interest | Total equity |
First half - 2026 | ||||||||
1 January 2026 | ( | ( | ||||||
Profit or loss for the period | – | – | – | – | ||||
Other comprehensive income, net of tax: | ||||||||
Equity instruments (losses)/gains | – | – | – | – | – | |||
Cash flow hedges (losses)gains | – | – | – | – | ||||
Remeasurements of defined benefit pension plans | – | – | – | – | – | |||
Currency retranslation (losses)/ gains(a) | – | – | – | ( | ||||
Total comprehensive income | – | – | – | |||||
Dividends on ordinary capital | – | – | – | – | ( | ( | – | ( |
Repurchase of shares(b) | – | – | – | ( | – | ( | – | ( |
Movements in treasury shares(c) | – | – | – | – | ( | ( | – | ( |
Share-based payment credit(d) | – | – | – | – | – | |||
Dividends paid to non-controlling interests | – | – | – | – | – | – | ( | ( |
Hedging loss/(gain) transferred to non- financial assets | – | – | – | ( | – | ( | ( | ( |
Other movements in equity(f) | – | – | – | ( | ( | ( | ||
30 June 2026 | ( | ( | ||||||
First half - 2025 | ||||||||
1 January 2025 | ( | ( | ||||||
Profit or loss for the period | – | – | – | – | ||||
Other comprehensive income, net of tax: | ||||||||
Equity instruments gains/(losses) | – | – | – | ( | – | ( | – | ( |
Cash flow hedges gains/(losses) | – | – | – | ( | – | ( | ( | ( |
Remeasurements of defined benefit pension plans | – | – | – | – | ( | ( | ( | ( |
Currency retranslation gains/ (losses)(a) | – | – | – | ( | ( | ( | ( | ( |
Total comprehensive income | – | – | – | ( | ||||
Dividends on ordinary capital | – | – | – | – | ( | ( | – | ( |
Repurchase of shares(b) | – | – | – | ( | – | ( | – | ( |
Movements in treasury shares(c) | – | – | – | ( | ( | – | ( | |
Share-based payment credit(d) | – | – | – | – | – | |||
Dividends paid to non-controlling interests | – | – | – | – | – | – | ( | ( |
Hedging loss/(gain) transferred to non- financial assets | – | – | – | ( | – | ( | ( | |
Other movements in equity(e) | – | – | – | ( | ( | ( | ||
30 June 2025 | ( | ( |
Consolidated balance sheet |
(unaudited) | |||
€ million | As at 30 June 2026 | As at 31 December 2025 | As at 30 June 2025 |
Non-current assets | |||
Goodwill | |||
Intangible assets | |||
Property, plant and equipment | |||
Pension asset for funded schemes in surplus | |||
Deferred tax assets | |||
Financial assets | |||
Other non-current assets | |||
Current assets | |||
Inventories | |||
Trade and other current receivables | |||
Current tax assets | |||
Cash and cash equivalents | |||
Other financial assets | |||
Assets held for sale | |||
Total assets | |||
Current liabilities | |||
Financial liabilities | |||
Trade payables and other current liabilities | |||
Current tax liabilities | |||
Provisions | |||
Liabilities held for sale | |||
Non-current liabilities | |||
Financial liabilities | |||
Non-current tax liabilities | |||
Pensions and post-retirement healthcare liabilities: | |||
Funded schemes in deficit | |||
Unfunded schemes | |||
Provisions | |||
Deferred tax liabilities | |||
Other non-current liabilities | |||
Total liabilities | |||
Equity | |||
Shareholders’ equity | |||
Non-controlling interests | |||
Total equity | |||
Total liabilities and equity |
Consolidated cash flow statement |
(unaudited) | First Half | |
€ million | 2026 | 2025(a) |
Net profit from continuing operations | ||
Taxation | ||
Share of net profit of joint ventures/associates and other (income)/loss from non-current investments and associates | ( | ( |
Net monetary loss arising from hyperinflationary economies | ||
Net finance costs | ||
Operating profit from continuing operations | ||
Depreciation, amortisation and impairment | ||
Changes in working capital | ( | ( |
Inventories | ( | ( |
Trade and other receivables (b) | ( | ( |
Trade payables and other liabilities (b) | ( | |
Pensions and similar obligations less payments | ||
Provisions less payments | ( | ( |
Elimination of loss/(profits) on disposals | ( | ( |
Non-cash charge for share-based compensation | ||
Other adjustments | ||
Cash flow from continuing operating activities | ||
Income tax paid on continuing operations | ( | ( |
Net cash flow from continuing operating activities | ||
Cash flow from operations attributable to discontinued operations | ( | |
Income tax paid from discontinued operation | ( | |
Net cash flow from discontinued operating activities | ( | |
Total cash flows from operating activities | ||
Interest received | ||
Purchase of intangible assets | ( | ( |
Purchase of property, plant and equipment | ( | ( |
Disposal of property, plant and equipment | ||
Acquisition of businesses and investments in joint ventures and associates | ( | ( |
Disposal of businesses, joint ventures and associates | ||
Acquisition of other non-current investments | ( | ( |
Disposal of other non-current investments | ||
Dividends from joint ventures, associates and other non-current investments | ||
Sale/(purchase) of financial assets | ( | |
Net cash flow used in continuing investing activities | ( | ( |
Net cash investing cash flows attributable to discontinued operations | ( | |
Total net cash (outflow)/inflow from investing activities | ( | ( |
Dividends paid on ordinary share capital | ( | ( |
Interest paid | ( | ( |
Net change in short-term borrowings | ||
Additional financial liabilities | ||
Repayment of financial liabilities | ( | ( |
Capital element of lease rental payments | ( | ( |
Repurchase of shares | ( | ( |
Other financing activities (c) | ( | ( |
Net cash flow used in continuing financing activities | ( | ( |
Net cash flow from discontinued financing activities | ||
Total net cash flow used in financing activities | ( | ( |
Net increase/(decrease) in cash and cash equivalents | ( | |
Cash and cash equivalents at the beginning of the period | ||
Effect of foreign exchange rate changes | ( | |
Cash and cash equivalents at the end of the period | ||
Notes to the condensed consolidated financial statements |
1.Accounting information and policies |
Notes to the condensed consolidated financial statements |
2.Segment information - Business Groups |
Second Quarter | Beauty & Wellbeing | Personal Care | Home Care | Foods | Total |
Turnover (€ million) | |||||
2025 | |||||
2026 | |||||
Change (%) | ( |
First Half | Beauty & Wellbeing | Personal Care | Home Care | Foods | Total |
Turnover (€ million) | |||||
2025 | |||||
2026 | |||||
Change (%) | ( | ||||
Operating profit (€ million) | |||||
2025 | |||||
2026 | |||||
Underlying operating profit (€ million) | |||||
2025 | |||||
2026 |
3.Segment information - Geographical area |
Second Quarter | Asia Pacific Africa | The Americas | Europe | Total |
Turnover (€ million) | ||||
2025 | ||||
2026 | ||||
Change (%) | ( |
First Half | Asia Pacific Africa | The Americas | Europe | Total |
Turnover (€ million) | ||||
2025 | ||||
2026 | ||||
Change (%) | ( | ( |
Notes to the condensed consolidated financial statements |
4.Taxation |
5.Earnings per share |
First Half | ||
2026 | 2025(a) | |
EPS – Basic | ||
Net profit attributable to shareholders’ equity (€ million) | ||
Average number of shares (millions of share units) | ||
EPS – basic (€) | ||
EPS – Basic from continuing operations | ||
Net profit from continuing operations attributable to shareholders’ equity (€ million) | ||
EPS – Basic from continuing operations (€) | ||
EPS – Basic from discontinued operations | ||
Net profit from discontinued operations attributable to shareholders’ equity (€ million) | ||
EPS – Basic from discontinued operations (€) | ||
EPS – Diluted | ||
Net profit attributable to shareholders’ equity (€ million) | ||
Adjusted average number of shares (millions of share units) | ||
EPS – diluted (€) | ||
EPS – Diluted from continuing operations | ||
Net profit from continuing operations attributable to shareholders’ equity (€ million) | ||
EPS – Diluted from continuing operations (€) | ||
EPS – Diluted from discontinued operations | ||
Net profit from discontinued operations attributable to shareholders’ equity (€ million) | ||
EPS – Diluted from discontinued operations (€) | ||
Millions | |
Number of shares at 31 December 2025 (net of treasury shares) | |
Shares repurchased under the share buyback programme | ( |
Net movements in shares under incentive schemes | |
Number of shares at 30 June 2026 (net of treasury shares) |
Notes to the condensed consolidated financial statements |
6.Demerger of the Ice Cream Business |
€ million | First Half | |
Total results from discontinued operations (Ice Cream) | 2026 | 2025 |
Turnover | ||
Operating (loss)/profit | ( | |
(Loss)/Profit before tax from discontinued operations | ( | |
Taxation | ( | |
(Loss)/Profit after taxation from discontinued operations | ( | |
Gain on disposal of discontinued operations | ||
Profit after taxation from discontinued operations | ||
Attributable to: | ||
Non-controlling interests | ( | |
Shareholders’ equity | ||
Earnings per share from discontinued operations (€) | ||
Diluted earnings per share from discontinued operations (€) | ||
Notes to the condensed consolidated financial statements |
7.Acquisitions and disposals |
Deal completion date | Acquired/disposed business |
2 February 2026 | Sold Graze, a healthy snacking brand in the UK to Katjes International GmbH & Co. |
12 February 2026 | HUL acquired the remaining based, and clean-label consumer wellness brand focused on the need spaces such as Lifestyle Protein, Hair & Beauty Supplements and Women’s health. |
2 March 2026 | Unilever Indonesia disposed its tea business in Indonesia operating under the SariWangi brand to PT Savoria Kreasi Rasa. |
16 March 2026 | Unilever disposed its Home Care business (powder detergents and liquids) in Central America and the Caribbean, including the Unisola manufacturing facility in El Salvador, to Industria La Popular (Guatemala). |
23 March 2026 | Sold portfolio of local soap brands (predominantly laundry bars), to SDTM CI, Ambition International Limited, and Aspiration Holding Limited. |
1 April 2026 | Sold the Group's shares in Kwality Wall’s (India) Limited (“KWIL”) to The Magnum Ice Cream Co.* |
1 April 2026 | Sold Unilever Ice Cream Comercial, Lda. (Portugal) to The Magnum Ice Cream Company.* |
1 June 2026 | Acquired position in the US Greens Supplement category. |
8.Share buyback |
Notes to the condensed consolidated financial statements |
9.Financial instruments |
30 June 2026 | 31 December 2025 | 30 June 2025 | |||||||
€ million | Current | Non- current | Total | Current | Non- current | Total | Current | Non- current | Total |
Cash and cash equivalents | |||||||||
Cash at bank and in hand | |||||||||
Short-term deposits(a) | |||||||||
Other cash equivalents(b) | |||||||||
Other financial assets | |||||||||
Financial assets at amortised cost(c) | |||||||||
Financial assets at fair value through other comprehensive income(d) | |||||||||
Financial assets at fair value through profit or loss: | |||||||||
Derivatives | |||||||||
Other(e) | |||||||||
Total financial assets(f) | |||||||||
Notes to the condensed consolidated financial statements |
9.Financial instruments (continued) |
Fair value | Carrying amount | |||||
€ million | As at 30 June 2026 | As at 31 December 2025 | As at 30 June 2025 | As at 30 June 2026 | As at 31 December 2025 | As at 30 June 2025 |
Financial assets | ||||||
Cash and cash equivalents | ||||||
Financial assets at amortised cost | ||||||
Financial assets at fair value through other comprehensive income | ||||||
Financial assets at fair value through profit and loss: | ||||||
Derivatives | ||||||
Other | ||||||
Financial liabilities | ||||||
Bank loans and overdrafts | ( | ( | ( | ( | ( | ( |
Bonds and other loans | ( | ( | ( | ( | ( | ( |
Lease liabilities | ( | ( | ( | ( | ( | ( |
Derivatives | ( | ( | ( | ( | ( | ( |
Other financial liabilities | ( | ( | ( | ( | ( | ( |
( | ( | ( | ( | ( | ( | |
As at 30 June 2026 | As at 31 December 2025 | As at 30 June 2025 | |||||||
€ million | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 |
Assets at fair value | |||||||||
Financial assets at fair value through other comprehensive income | |||||||||
Financial assets at fair value through profit or loss: | |||||||||
Derivatives(a) | |||||||||
Other | |||||||||
Liabilities at fair value | |||||||||
Derivatives(b) | ( | ( | ( | ||||||
Contingent consideration | ( | ( | ( | ||||||
Notes to the condensed consolidated financial statements |
10.Dividends |
Per Unilever PLC ordinary share (traded on the London Stock Exchange): | £ |
Per Unilever PLC ordinary share (traded on Euronext in Amsterdam): | € |
Per Unilever PLC American Depositary Receipt: | US$ |
Announcement Date | Ex-dividend Date for Ordinary Shares | Ex-dividend Date for ADRs | Record Date | Last Date for DRIP Election | Payment Date | |
Q2 2026 Dividend | 28 July 2026 | 06 August 2026 | 07 August 2026 | 07 August 2026 | 27 August 2026 | 18 September 2026 |
Q3 2026 Dividend | 28 October 2026 | 12 November 2026 | 13 November 2026 | 13 November 2026 | 27 November 2026 | 18 December 2026 |
11.Events after the balance sheet date |